Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes - Tremblay, André J.; Lamarche, Benoît; Deacon, Carolyn F.; Weisnagel, S. John; Couture, Patrick (Metabolism, clinical and experimental, 2014)
Keywords: Anti-Inflammatory Agents, Non-Steroidal - therapeutic use; Biological and medical sciences; Biomarkers - blood; Biomarkers - chemistry; Cell Adhesion Molecules - blood; Cell Adhesion Molecules - chemistry; Cross-Over Studies; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - immunology; Diabetes Mellitus, Type 2 - physiopathology; Diabetes. Impaired glucose tolerance; Dipeptidyl peptidase-4; Dipeptidyl-Peptidase IV Inhibitors - therapeutic use; Double-Blind Method; Down-Regulation - drug effects; E-Selectin - blood; Endocrine pancreas. Apud cells (diseases); Endocrinology & Metabolism; Endocrinopathies; Endothelium, Vascular - drug effects; Endothelium, Vascular - metabolism; Endothelium, Vascular - physiopathology; Etiopathogenesis. Screening. Investigations. Target tissue resistance; Feeding. Feeding behavior; Female; Fundamental and applied biological sciences. Psychology; Glucagon-Like Peptide 1 - agonists; Glucagon-Like Peptide 1 - blood; Humans; Inflammation; Inflammation Mediators - blood; Intercellular Adhesion Molecule-1 - blood; Intercellular Adhesion Molecule-1 - chemistry; Male; Medical sciences; Middle Aged; Phospholipases A2, Secretory - blood; Phospholipases A2, Secretory - metabolism; Pyrazines - therapeutic use; Sitagliptin; Sitagliptin Phosphate; Solubility; Triazoles - therapeutic use; Type 2 diabetes; Vertebrates: anatomy and physiology, studies on body, several organs or systems; CRP; FFA; Type 2 diabetes; Apo; GLP-1; IL-1; DPP-4; Sitagliptin; ICAM-1; Inflammation; IL-6; GIP; HDL; VCAM-1; TG; TNF-α; LDL; IL-18; VLDL; PAI-1; HOMA; sPLA2; Dipeptidyl peptidase-4; triglyceride; apolipoprotein; low density lipoprotein; C-reactive protein; interleukin-1; glucagon-like peptide-1; glucose-dependent insulinotropic polypeptide; interleukin-6; vascular cell adhesion molecule-1; soluble intercellular adhesion molecule-1; secreted phospholipase-A 2; dipeptidyl peptidase-4; homeostatic model assessment; plasminogen activator inhibitor-1; interleukin-18; free fatty acid; tumor necrosis factor-α; very low density lipoprotein; high density lipoprotein; Dipeptidyl-peptidase IV; Endocrinopathy; Human; Enzyme; Cell adhesion molecule; Enzyme inhibitor; Metabolic diseases; Marker; Peptidases; Hypoglycemic agent; Treatment; Gliptine derivatives; Hydrolases